AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 5 - (NewsRx.com & NewsRx.net) -- CD105/endoglin is a marker for endometrial cancer angiogenesis.
"Angiogenesis is a key process in tumor growth and metastasis, and factor-VIII microvascular density has been found to influence prognosis among endometrial carcinoma patients. The CD105/endoglin antibody has been reported to preferentially bind to activated endothelial cells in tissues participating in angiogenesis, and we therefore wanted to compare the prognostic significance of CD105/endoglin to that of factor-VIII," scientists in Norway stated.
"In a population-based endometrial carcinoma study with long (median 11.5 years) and complete patient follow-up, mean intratumor microvascular density (MVD) assessed using CD105/endoglin was investigated and compared with previous data for MVD assessed using factor-VIII. MVD by CD105/endoglin was significantly correlated with MVD by factor-VIII (p=0.001)," reported H.B. Salvesen and colleagues, Haukeland University Hospital, Department of Obstetrics and Gynecology.
"However, tumors within the two groups defined by the upper and lower quartiles for CD105/endoglin-MVD were both significantly more often metastatic (FIGO-stage III/IV, p=0.03), with high tumor cell proliferation by Ki67 (p=0.007) and with reduced survival (p=0.036) as compared with the intermediate groups. In Cox regression ...